JG
CHRS icon

Jefferies Group’s Coherus Oncology CHRS Stock Holding History

Jefferies Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-45,000
Closed -$730K – 1394
2020
Q1 		$730K Hold
45,000
– – 0.01% 1162
2019
Q4 		$810K Buy
45,000
+30,000
+200% +$553K 0.01% 1575
2019
Q3 		$304K Hold
15,000
– – ﹤0.01% 2175
2019
Q2 		$332K Buy
+15,000
New +$261K ﹤0.01% 1875
2017
Q3 		– Sell
-32,000
Closed -$459K – 2359
2017
Q2 		$459K Buy
32,000
+9,500
+42% +$183K ﹤0.01% 1645
2017
Q1 		$476K Buy
+22,500
New +$553K ﹤0.01% 1610
2016
Q4 		– Sell
-25,000
Closed -$670K – 2228
2016
Q3 		$670K Hold
25,000
– – ﹤0.01% 1480
2016
Q2 		$422K Buy
+25,000
New +$469K ﹤0.01% 1521

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jefferies Group's CHRS Position: Q1 2022 in Review

Jefferies Group sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 19,128 shares — an estimated $305K sold.

Jefferies Group first reported a position in CHRS in Q2 2016 and held it in 11 quarters. The position peaked at $1.53M in Q2 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Jefferies Group reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 19,128 Coherus Oncology shares in Q1 2022, an estimated $305K.
  • Jefferies Group first reported a position in Coherus Oncology in Q2 2016 and held it in 11 quarters.
  • Jefferies Group's Coherus Oncology position peaked at $1.53M in Q2 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.